Literature DB >> 29019111

Institutional Experience with Ostomies Created During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion.

Sam Pakraftar1, Lekshmi Ramalingam1, Yongli Shuai2, Heather L Jones1, James F Pingpank1, Steven S Ahrendt1, Matthew P Holtzman1, Amer H Zureikat1, Herbert J Zeh1, David L Bartlett1, Haroon A Choudry3.   

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) is a complex procedure that often requires ostomy creation to protect high-risk anastomoses. This study aimed to evaluate the authors' institutional experience with CRS-HIPEC-associated ostomies, determine predictors of ostomy creation and reversal, and assess their impact on survival.
METHODS: The study analyzed clinicopathologic, perioperative, and oncologic data from a prospective database of 1435 CRS-HIPEC procedures for peritoneal metastases. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with ostomy creation/reversal and survival.
RESULTS: Ostomies were created in 34% of the patients, most commonly loop ileostomies (82%). Loop ileostomies were reversed in the majority of patients (83%), whereas non-loop ileostomies were infrequently reversed (< 10% reversal rate). In a multivariate logistic regression model, intermediate or high tumor grade, colectomy/proctectomy, longer operative time, and lower Charlson comorbidity index were associated with loop ileostomy creation, whereas incomplete macroscopic resection, colorectal histology, and major postoperative complications were associated with non-reversal of loop ileostomy. In a multivariate Cox proportional hazards model, intermediate or high tumor grade and non-reversal of loop ileostomy were associated with worse overall survival.
CONCLUSIONS: Loop ileostomies were almost always reversed, whereas non-loop ileostomies were almost always permanent. Hospital readmissions for loop ileostomy-related complications were common. Therefore, formal outpatient protocols for prevention and management should be implemented. Non-reversal of loop ileostomy was associated with very poor survival.

Entities:  

Mesh:

Year:  2017        PMID: 29019111     DOI: 10.1245/s10434-017-6114-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Pelvic Anastomosis Without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Ekaterina Baron; Vadim Gushchin; Mary Caitlin King; Andrei Nikiforchin; Armando Sardi
Journal:  Ann Surg Oncol       Date:  2020-06-06       Impact factor: 5.344

2.  Failure to Thrive Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Causes and Consequences.

Authors:  Caroline J Rieser; Jurgis Alvikas; Heather Phelos; Lauren B Hall; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2022-01-06       Impact factor: 5.344

3.  What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?

Authors:  Patrick B Schwartz; Christopher C Stahl; Kara A Vande Walle; Courtney J Pokrzywa; Linda M Cherney Stafford; Taylor Aiken; James Barrett; Alexandra W Acher; Glen Leverson; Sean Ronnekleiv-Kelly; Sharon M Weber; Daniel E Abbott
Journal:  Ann Surg Oncol       Date:  2020-05-15       Impact factor: 5.344

4.  Impact of Socioeconomic Status on Presentation and Outcomes in Colorectal Peritoneal Metastases Following Cytoreduction and Chemoperfusion: Persistent Inequalities in Outcomes at a High-Volume Center.

Authors:  Caroline J Rieser; Richard S Hoehn; Mazen Zenati; Lauren B Hall; Eliza Kang; Amer H Zureikat; Andrew Lee; Melanie Ongchin; Matthew P Holtzman; James F Pingpank; David L Bartlett; M Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2021-03-09       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.